Kentucky Medicaid does not cover weight loss injections such as Wegovy or Zepbound when they are prescribed for weight loss. The state’s Medicaid pharmacy rules bar coverage of drugs used for “anorexia, weight loss, or weight gain,” and a 2026 attempt by Governor Andy Beshear’s administration to lift that ban was blocked by the legislature. GLP-1 drugs like Ozempic and Trulicity are on the formulary, but only for type 2 diabetes and a handful of other specific medical conditions.1KFF. Medicaid Coverage of and Spending on GLP-1s
The Weight Loss Exclusion
Kentucky’s Medicaid outpatient pharmacy program, governed by 907 KAR 23:010, explicitly excludes weight loss drugs. Federal law allows this: Section 1927(d)(2) of the Social Security Act lets state Medicaid programs leave weight loss medications off their formularies, and Kentucky has long taken that option. As of January 2026, only 13 state Medicaid programs covered GLP-1 drugs for obesity, and Kentucky was not one of them.1KFF. Medicaid Coverage of and Spending on GLP-1s
The exclusion runs through every managed care plan in the state. Passport by Molina Healthcare, one of Kentucky’s MCOs, tells providers that “drugs used for anorexia, weight loss, or weight gain are excluded from coverage” and singles out Wegovy and Saxenda as not covered because they have no diabetes indication.2Molina Healthcare. GLP-1 Receptor Agonist Coverage Updates The statewide Preferred Drug List administered by MedImpact for the Kentucky Department for Medicaid Services applies to all MCOs, so switching plans will not open a path to coverage.3MedImpact Healthcare Systems. Kentucky Medicaid Preferred Drug List
Which GLP-1 Drugs Kentucky Medicaid Will Pay For
Kentucky Medicaid covers several GLP-1 receptor agonists, but only to treat type 2 diabetes. Every one of them requires prior authorization, and approvals last six months. To qualify, you need a documented ICD-10 diagnosis of type 2 diabetes and an A1c of 6.5 or higher within the past six months. The prescribed dose cannot exceed the FDA-approved maximum for diabetes, which effectively blocks the higher doses used in weight management.4MedImpact Healthcare Systems. GLP-1 Receptor Agonists Prior Authorization Criteria
Preferred drugs are Ozempic, Trulicity, Victoza, and Byetta. Non-preferred drugs — Mounjaro, Rybelsus, Bydureon BCise, exenatide, and liraglutide — require documentation that the patient tried and failed at least two preferred agents over three or more months.4MedImpact Healthcare Systems. GLP-1 Receptor Agonists Prior Authorization Criteria
Enforcement runs at the pharmacy counter, not just on the paperwork. Since August 2023, Kentucky Medicaid has rejected GLP-1 claims at point of sale if a patient is on more than one drug in the class at once, or if the dose exceeds the FDA-approved maximum for type 2 diabetes.2Molina Healthcare. GLP-1 Receptor Agonist Coverage Updates
Narrow Non-Weight-Loss Uses of Wegovy and Zepbound
Kentucky Medicaid will cover Wegovy or Zepbound in a few tightly defined situations that have nothing to do with weight loss as the treatment goal. These are not backdoors for weight management.
Wegovy (semaglutide) can be approved to reduce the risk of major adverse cardiovascular events in patients 45 or older with a BMI of at least 27 and documented pre-existing cardiovascular disease. It can also be approved to treat metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced fibrosis. Under both pathways, patients with type 2 diabetes or an A1c of 6.5 or higher are excluded from these particular criteria, and the drug must be used with a reduced-calorie diet and more physical activity.5MedImpact Healthcare Systems. Wegovy Prior Authorization Criteria
Zepbound (tirzepatide) is covered to treat moderate to severe obstructive sleep apnea in adults with a BMI of 30 or higher who have tried and failed at least three months of CPAP or a similar breathing device. Patients with diabetes or an A1c of 6.5 or higher are again excluded from this pathway. The prescribing clinician has to be a sleep specialist or neurologist, or the patient has to be treated in consultation with one.6MedImpact Healthcare Systems. Zepbound Prior Authorization Criteria
An enrollee who simply wants to lose weight, even one with severe obesity, does not qualify under any of these criteria.
Obesity Treatments That Are Covered
Weight loss injections are excluded, but Kentucky Medicaid does pay for several other obesity treatments. Bariatric surgery — gastric bypass, gastric banding (Lap Band), and sleeve gastrectomy — is a covered benefit when it is medically necessary and prior authorized. Coverage criteria use the standard BMI thresholds: Class I obesity at 30, Class II at 35, and Class III at 40 or higher.7CareSource. Kentucky Covered Services Grid8UnitedHealthcare Community Plan. Bariatric Surgery Policy for Kentucky
Annual preventive visits include weight assessment and counseling referrals. Medical nutrition therapy from a registered dietitian is reimbursable in a clinic setting, behavioral assessment and intervention codes are covered, and Kentucky Medicaid pays for annual obesity screening and limited nutritional counseling tied to an obesity diagnosis or complications from obesity surgery.9GW Milken Institute School of Public Health. Medicaid Obesity Coverage – Kentucky7CareSource. Kentucky Covered Services Grid Diet pills and liquid diets are explicitly excluded.
Why Coverage Isn’t Changing
The Kentucky Cabinet for Health and Family Services approved an amendment to 907 KAR 23:010 on August 1, 2025, and filed it with the Legislative Research Commission on September 9, 2025. It would have struck the weight loss drug prohibition and let the Department for Medicaid Services manage utilization through prior authorization and step therapy. DMS estimated the change would cost the state about $1.1 million, projecting that roughly 2.5% of eligible enrollees would seek the drugs and only 32% would stay on therapy.10Kentucky Legislative Research Commission. 907 KAR 23:010 – Proposed Amendment
The Administrative Regulation Review Subcommittee found the regulation “deficient” on February 9, 2026.11Lexington Herald-Leader. Kentucky Senate Passes Bill to Block Medicaid Weight Loss Drug Coverage12Kentucky Legislative Research Commission. SB 65 Bill Record13Hoptown Chronicle. Final Round Up: Health-Related Bills Passed During 2026 Legislative Session The weight loss exclusion stays in place.
Federal policy did not open an alternative route. In December 2024, the Biden administration proposed a rule that would have required Medicaid programs to cover anti-obesity drugs, but the Trump administration finalized its 2026 Medicare and Medicaid policy on April 4, 2025, and declined to adopt that proposal, stating it was “not appropriate at this time.”14Healthcare Reimbursement Plus. Trump Administration Drops Proposal to Cover Anti-Obesity Drugs in Medicare Part D and Medicaid Programs Coverage of weight loss drugs is still a state decision, and Kentucky’s decision remains no.
What Would Have to Change
For Kentucky Medicaid to start covering weight loss injections like Wegovy or Zepbound for weight loss, either the legislature would have to repeal or amend the restriction now embedded in SB 65, or a new regulatory effort would have to clear administrative review that already rejected the last one. Until that happens, enrollees who want treatment for obesity itself have access to bariatric surgery, nutritional counseling, and behavioral interventions through Medicaid, but not to GLP-1 injections used for weight loss.